SNTA’s November Presentation Slide 25 says it all
Slide 25:
Drug/Pop Hazard Ratio Survival Improvement
Avastin 0.80 25%
G-All Adeno 0.68 47%
G- 6mo followup 0.56 79%
G-no smoke 0.48 108%
G-no l/b metastasis 0.41 144%
G-dx 6 mo 0.37 170%
(”G” = ganetespib)
Avastin’s annual sales are in the $6 billion neighborhood! Granted Avastin is used for 1st line NSCLC and ganetespib will be only used for 2nd line NSCLC at first, this still bodes very well for ganetespib (see slides 6&7).